Congenital heart block (CHB) is a rare disorder that may be associated with a high morbidity and even mortality, with a risk of death both in utero and during infancy. Women with serum titres of anti-Ro and/or anti-La antibodies carry a risk of CHB of 1–5% in their offspring, with a recurrence risk of approximately 20%. We present a case of a 36-year-old female with a pregnancy complicated by congenital heart block. Autoimmune profiling at booking showed she was positive for lupus anticoagulant and anti-Ro antibodies. A fetal echocardiogram at 21 + 3 showed complete heart block. She was monitored throughout the remainder of her pregnancy with serial growth scans, cardiovascular profiling, and BPP scoring. She had a normal vaginal delivery at term to a female infant.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mLOlJI
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
2016-09-24T01-16-18Z Source: International Journal of Research in Medical Sciences Biswajit Majumder, Viral Tandel, Sandip Ghosh, Sharmis...
-
by Alison M. Hixon, Guixia Yu, J. Smith Leser, Shigeo Yagi, Penny Clarke, Charles Y. Chiu, Kenneth L. Tyler In 2014, the United States exp...
-
This paper proposes an enhanced ant colony optimization with dynamic mutation and ad hoc initialization, ACODM-I, for improving the accuracy...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
Related Articles Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol. 2017 Apr 01;:394632017700431 Authors...
-
Hypopharyngeal Cancer Pharmaceutical and Healthcare Pipeline Review, H1 2017 Medgadget (blog) Latest Pharmaceutical and Healthcare di...
-
ACS Nano DOI: 10.1021/acsnano.7b02426 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h1neaG via...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου